双特异性抗体治疗复发/难治性多发性骨髓瘤的研究进展
Advances in bispecific antibody therapy for relapsed/refractory multiple myeloma
刘梦楠 1黄湘华1
作者信息
- 1. 国家肾脏疾病临床医学研究中心(南京,210016)
- 折叠
摘要
多发性骨髓瘤是骨髓浆细胞来源的血液系统恶性肿瘤,目前认为无法治愈且绝大多数患者最终发展为复发/难治性多发性骨髓瘤.双特异性抗体治疗是一种新兴的免疫治疗手段,在复发/难治性多发性骨髓瘤的治疗中已初步体现重要价值.本文就复发/难治性多发性骨髓瘤的发病机制、双特异性抗体的治疗机制及其研究进展进行综述,以期为多发性骨髓瘤的临床治疗提供新思路.
Abstract
Multiple myeloma is a hematologic malignancy originating from bone marrow plasma cells and remains incurable.Most patients eventually develop into relapsed/refractory multiple myeloma.Bispecific antibody therapy is a promising immunotherapeutic approach that has initially demonstrated significant efficacy.This article will review research progress of bispecific antibody in treatment of relapsed/refractory multiple myeloma.
关键词
双特异性抗体/复发/难治性多发性骨髓瘤/靶向治疗/临床试验Key words
bispecific antibody/relapsed/refractory multiple myeloma/targeted therapy/clinical trial引用本文复制引用
基金项目
国家自然科学基金面上项目(82270767)
出版年
2024
NETL
NSTL
万方数据